silodosin (rapaflo) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Silodosin is a selective antagonsit of alpha-1a adrenergic receptor which was developed by Kissei Pharmaceutical. The drug was approved by FDA under the name Rapaflo for the treatment of signs and symptoms associated with benign prostatic hyperplasia.   NCATS

Chemistry

  • SMILES: C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC3=CC=CC=C3OCC(F)(F)F
  • InChIKey: PNCPYILNMDWPEY-QGZVFWFLSA-N
  • Mol. Mass: 495.5345
  • ALogP: 3.07
  • ChEMBL Molecule:
    silodosin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.4073 - $0.8151

United States

$0.9132 - $8.3586
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide | kad 3213 | kmd 3213 | kmd-3213 | kso-0400 | rapaflo | silodoshin | silodosin | silodyx | urief | urorec

Organizations (47)

Research & Development (34)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (2)


 

Prostatic Hyperplasia

Urinary Bladder, Overactive

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Chronic Pain (Phase 2)

Kidney Calculi (Phase 3)

Nocturia (Phase 4)

Premature Ejaculation (Phase 2)

Prostatic Hyperplasia ()

Prostatic Neoplasms (Phase 3)

Ureteral Calculi (Phase 4)

Ureteral Diseases (Phase 4)

Ureterolithiasis (Phase 4)

Urinary Bladder, Neurogenic (Phase 4)

Urinary Calculi (Phase 2)

Urination Disorders (Phase 4)

Urolithiasis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 24
  • # of Trial Organizations: 34

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue